World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 5 June 2023
Main ID:  NCT00224393
Date of registration: 21/09/2005
Prospective Registration: No
Primary sponsor: The Cleveland Clinic
Public title: Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
Scientific title:
Date of first enrolment: February 2001
Target sample size: 60
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT00224393
Study type:  Interventional
Study design:  Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
Contacts
Name:     Mohamad A Hussein, MD
Address: 
Telephone:
Email:
Affiliation:  The Cleveland Clinic
Name:     John A Lust, MD, PhD
Address: 
Telephone:
Email:
Affiliation:  Mayo Clinic
Key inclusion & exclusion criteria

Inclusion Criteria:

- >=18 years of age.

- Laboratory values obtained <=14 days prior to registration.

- No limitation on the cardiac ejection fraction

- Bilirubin <3 mg/dL

- Absolute neutrophil count >=500/microliters

- Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy
of green bi-refringent material in Congo red-stained tissue specimens or
characteristic electron microscopy appearance.

- Demonstrable M-protein in the serum/urine or clonal population of plasma cells in the
bone marrow or immunohistochemical stain with anti-light chain anti-sera of amyloid
fibrils.

- ECOG performance status 0, 1, 2, or 3.

- Symptomatic organ involvement with amyloid to justify therapy. This could include
liver involvement, cardiac involvement, renal involvement, peripheral neuropathy, or
soft tissue involvement. Must have more than purpura or carpal tunnel syndrome.

- Previously treated or untreated. No limit to prior therapy provided there is adequate
residual organ function.

- Ability to provide informed consent.

- Ability to self-inject medication or have a caregiver who can administer the drug.

Exclusion Criteria:

- Amyloid-specific syndrome, such as, carpal tunnel syndrome or skin purpura as only
evidence of disease. The finding of vascular amyloid only in a bone marrow biopsy
specimen or in a plasmacytoma is not indicative of systemic amyloidosis.

- Presence of non-AL amyloidosis.

- Melphalan or other alkylating agents, high-dose dexamethasone or alpha interferon <=4
weeks prior to registration.

- Concurrent use of corticosteroids, but patients may be on chronic steroids if they are
being given for disorders other than amyloid, i.e., adrenal insufficiency, rheumatoid
arthritis, etc.

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception (condoms, diaphragm, birth control pills, injections, intrauterine
device [IUD], surgical sterilization, abstinence, etc.)

- Uncontrolled infection.

- Clinically overt multiple myeloma (monoclonal BMPC >30%), and at least one of the
following:

- Bone lesions

- Hypercalcemia

- Active malignancy with the exception of adequately treated basal cell or squamous cell
skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from
which the patient is currently in complete remission, or any other cancer from which
the patient has been disease-free for 5 years.



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Primary Systemic Amyloidosis
Intervention(s)
Drug: Enbrel
Primary Outcome(s)
clinical efficacy
Secondary Outcome(s)
Evaluate overall survival
Identify prognostic factors
Duration of response and time to progression
Evaluate qualitative and quantitative toxicities of Enbrel
Secondary ID(s)
MC018A
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey